Huasun(SZ:000790) Zheng Quan Zhi Xing·2025-08-01 16:35Transaction Overview - The company plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., to focus resources on core business and enhance profitability [1][2] - The initial transfer price is set at RMB 63.78 million based on an asset appraisal [1][6] Financial Performance of the Target Company - The target company's total assets increased from RMB 12,287.27 million to RMB 15,871.39 million over the last year [5] - Total liabilities rose from RMB 7,519.00 million to RMB 11,392.73 million [5] - Net profit for the last audited year was RMB 1,678.43 million, up from RMB 289.61 million [5] Asset Valuation - The valuation of the 51% equity stake is based on an appraisal conducted by Walker (Beijing) International Asset Appraisal Co., Ltd., using both asset-based and income approaches [6] - The assessed value of the target company's total equity is RMB 125.06 million, with an increase of RMB 77.38 million, representing a growth rate of approximately 164.5% [6] Approval Process - The proposal for the equity transfer requires approval from the company's shareholders' meeting before execution [2][8] - The independent directors and supervisory board have expressed support for the transaction, confirming that it aligns with the company's strategic goals and does not harm shareholder interests [7][8] Future Implications - If the transaction is completed, the target company will no longer be included in the company's consolidated financial statements [6] - The transaction is seen as a necessary step for optimizing the company's investment structure and enhancing its operational capabilities [8]